LPA and non-small cell lung carcinoma: The ATX and LPA receptors inhibitor BrP-LPA we used has also been studied in A549 non-small cell lung cancer [27] and MDA-MB-231 breast cancer [38] cells at doses ranging from 10 to 40 μM, but its effects have never been studied in endothelial cells or in conjunction with radiation.